Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Valerina Changarathil

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

November 15, 2024
Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.
Read Transcript

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Vihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie Douvis
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
Antipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John Feder
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
October 21, 2024

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
 ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 8, 2024

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More